{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:23:49Z","timestamp":1787725429568,"version":"build-2784847793"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The current hepatitis B (HBV) and hepatitis C virus (HCV) screening practices may fail to detect many infected patients who could benefit from new therapeutic agents to limit progression to cirrhosis and hepatocellular carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study assessed the test positivity rate and cascade of care of viral hepatitis patients in primary care in a low endemic region as well as the testing policy of abnormal alanine aminotransferase (ALT) level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective clinical audit among primary health care practices in Flanders, Belgium, assessing patients with an active medical file between 2019 and 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 84\/89 (94.4%) primary health care practices participated representing 621,573 patients of which 1069 patients (0.17%) were registered as having viral hepatitis, not further specified. Detailed information was available from 38 practices representing 243,723\/621,573 (39.2%) patients of which 169 (0.07%) were HBsAg positive and 99 (0.04%) anti-HCV positive. A total of 96\/134(71.6%) chronic HBV-infected and 31\/77(40.3%) chronic HCV-infected patients were referred to a hepatologist. A total of 30,573\/621,573(4.9%) patients had an abnormal ALT level, and by at random selection, more detailed information was obtained on 211 patients. Information on high-risk groups was missing in up to 60%. In patients with abnormal ALT level, HBsAg and anti-HCV testing were conducted in 37\/211(17.5%) and 25\/211(11.8%), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a low endemic region, the testing rate and cascade of care of HBV and HCV-infected patients can be improved in primary care, especially in high-risk groups and patients with abnormal ALT levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmae019","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:32:41Z","timestamp":1718703161000},"page":"693-701","source":"Crossref","is-referenced-by-count":1,"title":["Clinical audit of quality of care among patients with viral hepatitis in primary care in a low endemic region"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-5703","authenticated-orcid":false,"given":"\u00d6zg\u00fcr M","family":"Koc","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Centre , Maastricht ,","place":["the Netherlands"]},{"name":"School of Nutrition and Translational Research in Metabolism (NUTRIM), University Maastricht , Maastricht ,","place":["the Netherlands"]},{"name":"Faculty of Medicine and Life Sciences, Hasselt University , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Vaes","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Robaeys","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Life Sciences, Hasselt University , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian F","family":"Catalan","sequence":"additional","affiliation":[{"name":"Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Aertgeerts","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"CEBAM, Belgian Centre for Evidence Based Medicine, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"1","key":"2024100903334799100_CIT0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study","volume":"219","author":"Nguyen","year":"2019","journal-title":"J Infect Dis"},{"issue":"2","key":"2024100903334799100_CIT0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2024100903334799100_CIT0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"issue":"5","key":"2024100903334799100_CIT0004","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"2024100903334799100_CIT0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2024100903334799100_CIT0006","volume-title":"Public health guidance on HIV, hepatitis B and C testing in the EU\/EEA \u2013 An integrated approach","author":"European Centre for Disease Prevention and Control","year":"2018"},{"issue":"1","key":"2024100903334799100_CIT0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2468-1253(18)30318-2","article-title":"Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial","volume":"4","author":"Flanagan","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"619","key":"2024100903334799100_CIT0008","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.3399\/bjgp14X677112","article-title":"Case-finding for hepatitis C in primary care: a mixed-methods service evaluation","volume":"64","author":"Datta","year":"2014","journal-title":"Br J Gen Pract"},{"issue":"5","key":"2024100903334799100_CIT0009","doi-asserted-by":"crossref","first-page":"e026464","DOI":"10.1136\/bmjopen-2018-026464","article-title":"Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study","volume":"9","author":"Bielen","year":"2019","journal-title":"BMJ Open"},{"issue":"10","key":"2024100903334799100_CIT0010","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/intqhc\/mzaa128","article-title":"The effect of electronic audits and feedback in primary care and factors that contribute to their effectiveness: a systematic review","volume":"32","author":"Van Den Bulck","year":"2020","journal-title":"Int J Qual Health Care"},{"key":"2024100903334799100_CIT0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejim.2022.04.024","article-title":"Hepatitis C Elimination in the Netherlands (CELINE): how nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination","volume":"101","author":"Isfordink","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2024100903334799100_CIT0012","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/liv.14016","article-title":"Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium","volume":"39","author":"Bielen","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"2024100903334799100_CIT0013","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"2024100903334799100_CIT0014","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"30","key":"2024100903334799100_CIT0015","doi-asserted-by":"crossref","first-page":"1900064","DOI":"10.2807\/1560-7917.ES.2019.24.30.1900064","article-title":"Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017","volume":"24","author":"Koc","year":"2019","journal-title":"Euro Surveill"},{"key":"2024100903334799100_CIT0016","volume-title":"Hepatitis B","author":"World Health Organization","year":"2022"},{"key":"2024100903334799100_CIT0017","volume-title":"Hepatitis C","author":"World Health Organization","year":"2022"},{"issue":"3","key":"2024100903334799100_CIT0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10654-007-9105-6","article-title":"A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium","volume":"22","author":"Quoilin","year":"2007","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"2024100903334799100_CIT0019","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jmv.25457","article-title":"Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: importance of migration","volume":"91","author":"Koc \u00d6","year":"2019","journal-title":"J Med Virol"},{"issue":"3","key":"2024100903334799100_CIT0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1007393405966","article-title":"Prevalence of hepatitis A, B and C in the Flemish population","volume":"13","author":"Beutels","year":"1997","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"2024100903334799100_CIT0021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/17843286.2020.1763670","article-title":"Hepatitis C in two general practices in Flanders, Belgium: is there a need to reconsider current screening recommendations","volume":"76","author":"Botterman","year":"2021","journal-title":"Acta Clin Belg"},{"issue":"1","key":"2024100903334799100_CIT0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12889-018-6347-z","article-title":"Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up","volume":"19","author":"Litzroth","year":"2019","journal-title":"BMC public health"},{"issue":"1","key":"2024100903334799100_CIT0023","first-page":"99","article-title":"Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders","volume":"82","author":"Verhelst","year":"2019","journal-title":"Acta Gastroenterol Belg"},{"issue":"8","key":"2024100903334799100_CIT0024","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/cid\/civ002","article-title":"Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study","volume":"60","author":"Smith","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2024100903334799100_CIT0025","first-page":"548","article-title":"HCV screening practices and prevalence in an MCO, 2000-2007","volume":"17","author":"Roblin","year":"2011","journal-title":"Am J Manag Care"},{"issue":"12","key":"2024100903334799100_CIT0026","first-page":"359","article-title":"Screening, linkage to care and treatment of hepatitis C infection in primary care setting in the South of Italy","volume":"10","author":"Citarella","year":"2020","journal-title":"Life (Basel)"},{"key":"2024100903334799100_CIT0027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejim.2018.02.015","article-title":"Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas","volume":"53","author":"Andriulli","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2024100903334799100_CIT0028","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jvh.13427","article-title":"Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016","volume":"28","author":"Reyes-Urue\u00f1a","year":"2021","journal-title":"J Viral Hepat"},{"issue":"14","key":"2024100903334799100_CIT0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12688\/f1000research.15892.1","article-title":"Hepatitis C elimination: challenges with under-diagnosis and under-treatment","volume":"8","author":"Terrault","year":"2019","journal-title":"F1000Res"},{"issue":"9","key":"2024100903334799100_CIT0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"2024100903334799100_CIT0031","doi-asserted-by":"crossref","first-page":"e026464","DOI":"10.1136\/bmjopen-2018-026464","article-title":"Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study","volume":"9","author":"Bielen","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"2024100903334799100_CIT0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.amjmed.2014.01.012","article-title":"Hepatitis C screening trends in a large integrated health system","volume":"127","author":"Linas","year":"2014","journal-title":"Am J Med"},{"issue":"8","key":"2024100903334799100_CIT0033","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/jvh.12885","article-title":"Impact of electronic reminder systems on hepatitis C screening in primary care","volume":"25","author":"MacLean","year":"2018","journal-title":"J Viral Hepat"},{"issue":"19","key":"2024100903334799100_CIT0034","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jama.2023.2806","article-title":"Universal adult hepatitis B screening and vaccination as the path to elimination","volume":"329","author":"So","year":"2023","journal-title":"JAMA"},{"issue":"22","key":"2024100903334799100_CIT0035","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1001\/jama.2020.3693","article-title":"Updated CDC recommendations for universal hepatitis C virus screening among adults and pregnant women: implications for clinical practice","volume":"323","author":"Havens","year":"2020","journal-title":"JAMA"},{"key":"2024100903334799100_CIT0036","volume-title":"Guidelines on hepatitis B and C testing","author":"World Health Organization","year":"2017"},{"issue":"18","key":"2024100903334799100_CIT0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2334-13-181","article-title":"Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening","volume":"13","author":"Hahn\u00e9","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2024100903334799100_CIT0038","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/fampra\/cmq006","article-title":"A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign","volume":"27","author":"Helsper","year":"2010","journal-title":"Fam Pract"},{"issue":"1","key":"2024100903334799100_CIT0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10900-017-0385-9","article-title":"The Role of Primary Health Care in Hepatitis B Testing and Management: A Case Study","volume":"43","author":"Richmond","year":"2018","journal-title":"J Community Health"},{"issue":"6","key":"2024100903334799100_CIT0040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.cgh.2020.09.011","article-title":"eHealth technologies for screening, diagnosis, and management of viral hepatitis: a systematic review","volume":"19","author":"Haridy","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2024100903334799100_CIT0041","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2024100903334799100_CIT0042","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archinternmed.2007.131","article-title":"Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels","volume":"168","author":"Neuschwander-Tetri","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"2024100903334799100_CIT0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024100903334799100_CIT0044","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.23505","article-title":"Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"2024100903334799100_CIT0045","first-page":"693","article-title":"Liver function testing in a working population: three strategies to reduce false-positive results","volume":"30","author":"Wright","year":"1988","journal-title":"J Occup Med"},{"issue":"1","key":"2024100903334799100_CIT0046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2024100903334799100_CIT0047","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"issue":"28","key":"2024100903334799100_CIT0048","doi-asserted-by":"crossref","first-page":"i-xiv, 1","DOI":"10.3310\/hta17280","article-title":"Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study","volume":"17","author":"Lilford","year":"2013","journal-title":"Health Technol Assess"},{"issue":"7","key":"2024100903334799100_CIT0049","doi-asserted-by":"crossref","first-page":"e0234740","DOI":"10.1371\/journal.pone.0234740","article-title":"Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium","volume":"15","author":"Koc \u00d6","year":"2020","journal-title":"PLoS One"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/41\/5\/693\/59644782\/cmae019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/41\/5\/693\/59644782\/cmae019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:34:04Z","timestamp":1728444844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/41\/5\/693\/7695381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmae019","relation":{},"ISSN":["1460-2229"],"issn-type":[{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,17]]}}}